Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00127036 · ClinicalTrials.gov registry record · Phase 2
Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT00127036 is a Phase 2 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 65 participants.
The verdict
NCT00127036, a Phase 2 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the investigators can predict the sensitivity or resistance of colon cancer to the two available first line chemotherapy agents.
Interventions
- DRUG Bevacizumab
- DRUG XELOX
- DRUG XELIRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2003-10 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00127036
The ClinicalTrials.gov registry entry for NCT00127036 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00127036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00127036 about?
NCT00127036 is a clinical study titled "Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)". The purpose of this study is to determine if the investigators can predict the sensitivity or resistance of colon cancer to the two available first line chemotherapy agents.
What is the current status of trial NCT00127036?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2003-10. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00127036?
The interventions under investigation include: Bevacizumab (DRUG), XELOX (DRUG), XELIRI (DRUG).
Who is sponsoring clinical trial NCT00127036?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.